All News

Article

Health inequities in rheumatology: A central theme

Mrinalini Dey, MBBChir, MA(Hons) Cantab., MRCP, FHEA Jun 11, 2025

This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases. Across multiple sessions and studies, delegates are presenting compelling evidence and ground-breaking research demonstrating that who you are, where you live, and what resources you can access truly do shape the trajectory of chronic illness just as much as biological factors.

3 Fs of diagnosis of #HLH -Fever -Ferritin -Falling blood count Raising awareness is the key! Especially in rare diseases like this where the morbidity and mortality is super high! Collaboration between specialists help HLH networks will be helpful like this @RheumNow #EULAR2025 https://t.co/HWbvIma3yx

https://x.com/bella_mehta/status/1933142076620689873/photo/1

Treatment strategies for steroid free management of #relapsingpolychondritis 56 patients from a single center #POS0149 #EULAR2025 @RheumNow https://t.co/d4I56opS02

https://x.com/bella_mehta/status/1933157207526563956/photo/1

?fishing for + results #EULAR2025 ⚠️opinion be aware that results do not live or die on P values Impt findings beyond primary endpoints may be Impt beyond P<0.05 Conversely Unexpected P values in a database ❎interpret w caution Consider as hypothesis only @RheumNow

#HOT topic Lung 🫁 #ultrasound for #RA #ILD #LUS B lines vs HRCT Single site 🇫🇷 study V sensitive & specific 🤔needs standardization & comparison in other groups Abst#POS-180 #EULAR2025 @RheumNow @eular_org https://t.co/PwGE4rgk40

https://x.com/Janetbirdope/status/1933150999352369385/photo/1

In D2T-PsA (10%), 57% had persistent inflammation (PIPsA), 43% non-inflammatory (NIPsA). Ultrasound distinguished phenotypes: median US activity score 3.22 vs 0.88.,swollen joints 2.5 vs 0, tender points higher in NIPsA. Abstract OP0176 @RheumNow #EULAR2025 https://t.co/k7m8gAzbAZ

https://x.com/synovialjoints/status/1933123344791961949/photo/1

Difficult-to-treat & early PsA at #EULAR2025 GRAPPA definitions: D2T-PsA (≥3 therapies incl ≥2 b/tsDMARDs with persistent inflammation); C2M-PsA (broader: comorbidities, pain, intolerance). 95% GRAPPA consensus. Abstact OP0175 @RheumNow #EULAR2025 https://t.co/eqKmMPh80x

https://x.com/synovialjoints/status/1933122057648115888/photo/1

▶️Erosive hand OA 🔺Gull-wing erosion @ DIPJs ✅ 🔺Saw-tooth erosions @ PIPJs ✅ #OA #Osteoarthritis #EULAR2025 https://t.co/5Hh4Ki9P8V

https://x.com/gurdeep_dulay/status/1933094295369605204/photo/1

Secukinumab Use in Refractory Giant Cell Arteritis In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/pG3aN3o4GZ

1 shot will do! #symptomatic #Knee #OA given #gene #therapy #intra-#articular Seemed to last up to 104 weeks! But no placebo small safety study but sustained #WOMAC responses Needs large #RCT but v interesting #EULAR2025 @RheumNow @eular_org Abst# POS0492 https://t.co/hqTqBorrbA

Secukinumab for PMR? -post hoc analysis of the TitAIN study (phase 2 RCT on new onset/relapsing GCA) showed: -Numerical reduction in patients experiencing PMR symptoms when treated with secukinumab compared to placebo. -Safety profile was similar to the overall GCA study

Real-world study on dual bDMARD plus JAKi or TYK2i combinations in refractory PsA. 22 PsA patients on dual bDMARD + JAKi/TYK2i: •Most common: IL-17i + TYK2i •Total exposure: 8.5–10.5 pt-years •Only mild URIs/stomatitis •Clinical improvements seen in joint/skin domains https://t.co/waDReDqSDE

https://x.com/synovialjoints/status/1932914389482401852/photo/1

🔬 Proud to present our poster at #EULAR2025! 📌 Serum KL-6 and IL-18 as Diagnostic and Prognostic Biomarkers in Systemic Sclerosis-Associated ILD: A 24-Month Cohort Study KL-6 and IL-18 show promising roles in tracking ILD progression and lung function decline in #SSc 📍F.136 https://t.co/woTMnTkRKY

https://x.com/cristianasieiro/status/1932759928067789058/photo/1

Got paraproteinemia? Here’s what to think about, from a rheumatology point of view. @RheumNow #EULAR2025 https://t.co/eu7Mi5yeum

https://x.com/drdavidliew/status/1932788489709306341/photo/1

POCUS of the lung can detect subclinical ILD and can be a useful, inexpensive, easy to perform screening tool for CTD-ILD. #EULAR2025 @RheumNow https://t.co/KpH05w1S9O

https://x.com/AdelaCastro222/status/1932799331133800941/photo/1

LIVE Daily Recap – EULAR 2025 Coverage Date: Thursday, 06/12, Friday, 06/13 and Saturday, 06/14 Time: 12 (noon) ET 🔗 Tune in and join the conversation: YouTube, X, Facebook Live & LinkedIn #RheumNow#EULAR25 #Rheumatology #MedTwitter #HCPs #RheumatologyEducation https://t.co/1qlcKDOL64

Closing the care divide in #JIA treatment plenary session Overall theme in #EULAR2025 is everyone talking about AI and digital health on day 1 Biologics have changed the game! @RheumNow https://t.co/qDqbz8JApe

https://x.com/bella_mehta/status/1932796681499914393/photo/1

Data from a German cohort evaluated the frequency of D2M-axSpA using the new D2M definition and showed: > Female pts > Peripheral SpA symptoms < HLAB27 positive < Education level < Objective signs: MRI-inflammation in the spine or elevated CRP levels. also PROs were worse in

Young Patients’ AREA empowers teens/young adults w/ autoimmune disease to shape research. US-based, youth-led & grounded in empowerment, they co-design studies, train peers & advise researchers. A truly positive and meaningful initiative esp for PPIE @RheumNow #EULAR2025 #OP0008

Repurposing drugs to #osteoarthritis No jewel in the rough! Most drugs - MTX, colchicine, TNFi, IL1i, etc are NEGATIVE or yield mixed results from diff #RCTs Not sure this is the way forward for #OA drug discovery 💡 #EULAR2025 @RheumNow @eular_org Abst#POS565 https://t.co/A6SdXtOo7v

https://x.com/Janetbirdope/status/1932821338445771088/photo/1

Topics

All News

Health inequities in rheumatology: A central theme

Do you get our email newsletter?